Clinical trials sponsored by Dizal Pharmaceuticals

Phase breakdown

Conditions studied

Recruiting trials led by Dizal Pharmaceuticals

• A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)
  NCT06295432 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
  NCT06813365 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
  NCT06276283 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials is Dizal Pharmaceuticals recruiting for?

Dizal Pharmaceuticals is the lead sponsor of 3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.